Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Low-Dose Radiotherapy Combined With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: An Exploratory Phase II Study

NCT07682376 is registered in ClinicalTrials.gov with Harbin Medical University as lead sponsor.

NCT NCT07682376
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07682376 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Low-Dose Radiotherapy Combined With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: An Exploratory Phase II Study
Lead sponsor
Harbin Medical University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 10, 2026
Completion date
May 30, 2029
Enrollment
96 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal squamous cell carcinoma (escc)